NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 05/16/2025 at 12:30, 1 year 1 month ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials

NanoViricides NV-387 Financials Form 10-Q Phase II Trial
BRIEF

published on 05/14/2025 at 12:35, 1 year 1 month ago

NanoViricides Advances with Broad-Spectrum Antiviral Drug NV-387

Antiviral Drugs MPOX Treatment Measles Outbreak NV-387 Development Global Health Strategy
BRIEF

published on 05/14/2025 at 12:35, 1 year 1 month ago

NanoViricides progresse avec le médicament antiviral à large spectre NV-387

Médicaments Antiviraux Traitement MPox Épidémie De Rougeole Développement NV-387 Stratégie Mondiale En Matière De Santé
PRESS RELEASE

published on 05/14/2025 at 12:30, 1 year 1 month ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387

NanoViricides NV-387 Antiviral Nanomedicine Viral Infections
BRIEF

published on 05/08/2025 at 12:35, 1 year 1 month ago

Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NV-387 Clinical Trial Antiviral Drug Mpox Democratic Republic Of Congo
BRIEF

published on 05/08/2025 at 12:35, 1 year 1 month ago

Approbation de l'essai clinique de phase II du NV-387 de NanoViricides en RDC

NV-387 Essai Clinique Mpox Médicament Antiviral République Démocratique Du Congo
PRESS RELEASE

published on 05/08/2025 at 12:30, 1 year 1 month ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities

NanoViricides, CNES Approval, Phase II Clinical Trial, NV-387, MPox Disease
BRIEF

published on 04/29/2025 at 12:35, 1 year 2 months ago

Potential Breakthrough in Measles Treatment: NanoViricides Develops Antiviral Drug

NanoViricides NV-387 Antiviral Drug Measles Treatment Endemic Disease
BRIEF

published on 04/29/2025 at 12:35, 1 year 2 months ago

Avancée potentielle dans le traitement de la rougeole : NanoViricides développe un médicament antiviral

NanoViricides NV-387 Médicament Antiviral Traitement De La Rougeole Maladie Endémique
PRESS RELEASE

published on 04/29/2025 at 12:30, 1 year 2 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides, Inc. provides details on its Measles drug development program targeting the endemic potential of the virus in the USA and the effectiveness of their broad-spectrum antiviral drug NV-387

NV-387 NanoViricides Inc. Broad-spectrum Antiviral Measles Drug Development Vaccination Decline

Published on 06/30/2026 at 15:00, 1 hour 8 minutes ago

Four Nines Gold Advances Toward Maiden Drill Program with Property-Wide Geophysical Survey at Hayden Hill
Published on 06/30/2026 at 15:00, 1 hour 8 minutes ago

BlackBerry AtHoc Strengthens Enterprise Readiness as Cyber, Climate, and Geopolitical Uncertainty Rises
Published on 06/30/2026 at 15:00, 1 hour 8 minutes ago

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Published on 06/30/2026 at 14:30, 1 hour 38 minutes ago

NV Gold Announces Non-Brokered Private Placement
Published on 06/30/2026 at 14:00, 2 hours 8 minutes ago

Datametrex Announces Completion of AI-Based Evaluation of 2 Patents and Launch of Licensing Initiative

View all ACCESSWIRE

Published on 06/30/2026 at 15:37, 31 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 06/30/2026 at 15:34, 34 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 06/30/2026 at 15:29, 38 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 06/30/2026 at 15:26, 42 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 06/30/2026 at 14:46, 1 hour 22 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc

View all EQS

Published on 06/30/2026 at 15:06, 1 hour 2 minutes ago

260630 BENETEAU Transactions sur actions propres
Published on 06/30/2026 at 07:30, 8 hours 38 minutes ago

Gimv sells its stake in AlpenBlu Clinics (formerly Les Psy Réunis), a Swiss provider of outpatient mental healthcare, to Impact Healthcare.
Published on 06/30/2026 at 07:30, 8 hours 38 minutes ago

Gimv cède sa participation dans AlpenBlu Clinics (précédemment Les Psy Réunis), acteur suisse des soins ambulatoires en santé mentale, à Impact Healthcare
Published on 06/30/2026 at 07:30, 8 hours 38 minutes ago

Acquisition of Harwanne Capital Management
Published on 06/30/2026 at 07:30, 8 hours 38 minutes ago

Acquisition de Harwanne Capital Management

View all LES ECHOS COMFI WIRE

News